Home / Recalls / Novitium Pharma LLC / D-0389-2024

D-0389-2024 Class III Terminated

Recalled by Novitium Pharma LLC — East Windsor, NJ

Recall Details

Product Type
Drugs
Report Date
March 27, 2024
Initiation Date
March 4, 2024
Termination Date
March 21, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,940 1000-count bottles

Product Description

Digoxin Tablets, USP 125mcg, (0.125 mg), 1000-count bottle, Rx Only, Manufactured by: Novitium Pharma LLC., 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-201-20

Reason for Recall

Cross Contamination with Other Products:(mycophenolate mofetil).

Distribution Pattern

Nationwide in the USA

Code Information

Lot #: M23172A, Exp 01/31/2025

Other recalls by Novitium Pharma LLC

  • D-0443-2024 Class III — Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactu (March 25, 2024)
  • D-0311-2020 Class II — Novitium Pharma Ranitidine Capsules 150 mg 500 capsules Rx Only Manufactured by: (October 25, 2019)
  • D-0312-2020 Class II — Novitium Pharma Ranitidine Capsules 300 mg 30 capsules Rx Only Manufactured by: (October 25, 2019)
  • D-0310-2020 Class II — Novitium Pharma Ranitidine Capsules 150 mg 60 capsules Rx Only Manufactured by: (October 25, 2019)
  • D-0313-2020 Class II — Novitium Pharma Ranitidine Capsules 300 mg 100 capsules Rx Only Manufactured by: (October 25, 2019)